Here's your US drug review and approval news for the week in brief: Sandoz Inc. finally can take its turn to celebrate, as the Novartis AG unit scored a long-awaited approval for its biosimilar of Amgen Inc.'s Neulasta (pegfilgrastim).
The Center for Drug Evaluation and Research (CDER) also cleared two more novel agents last week, granting approvals to Celgene Corp.'s Reblozyl (luspatercept–aamt) and Giskit B.V
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?